CXCR4 and cancer: It was found that X4-2-6 peptide-based nanoparticles could inhibit CXCR4 function in vitro and hamper CXCR4-dependent bone metastasis of MDA-MB-231 cancer cells and prolong the survival in a mouse model of metastatic breast cancer.